CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY - USD ($) $ in Millions	Total	Common stock	Capital in excess of par value	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss) income	Treasury stock	Non-controlling interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares						21,588,147
Beginning balance , common stock (in shares) at Dec. 31, 2020		(128,526,137)
Beginning balance at Dec. 31, 2020	$ 6,322	$ 16	$ 3,853	$ 4,156	$ (698)	$ (1,017)	$ 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	273			270			3
Cumulative translation adjustment	(848)				(848)
Gains (losses) on derivatives qualifying as hedges, net of tax	8				8
Pension liability and postretirement adjustment; net of tax	115				115
Cash dividends declared	(785)			(785)
Stock options/SSARs (in shares)						159,222
Stock options/SSARs	11		4			$ 7
Impact of N&B Merger (in shares)		141,740,461
Purchase of NCI	15,976	$ 18	15,936				22
Conversion of tangible equity units (in shares)		5,460,031
Conversion of tangible equity units	0	$ 1	(1)
Vested restricted stock units and awards	(5)		(18)			$ 13
Vested restricted stock units and awards (in shares)						276,280
Stock-based compensation	54		54
Redeemable NCI	(2)		(2)
Dividends on non-controlling interest and other	(2)						(2)
Ending balance (in shares) at Dec. 31, 2021		(275,726,629)
Ending balance at Dec. 31, 2021	21,117	$ 35	19,826	3,641	(1,423)	$ (997)	35
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares						21,152,645
Net (loss) income	(1,868)			(1,871)			3
Cumulative translation adjustment	(933)				(933)
Gains (losses) on derivatives qualifying as hedges, net of tax	0
Pension liability and postretirement adjustment; net of tax	158				158
Cash dividends declared	(815)			(815)
Stock options/SSARs (in shares)						85,728
Stock options/SSARs	15		11			$ 4
Vested restricted stock units and awards	(26)		(41)			$ 15
Vested restricted stock units and awards (in shares)						308,751
Stock-based compensation	49		49
Purchase of NCI	(5)		1				(6)
Redeemable NCI	(5)		(5)
Dividends on non-controlling interest and other	(2)						(2)
Ending balance (in shares) at Dec. 31, 2022		(275,726,629)
Ending balance at Dec. 31, 2022	$ 17,685	$ 35	19,841	955	(2,198)	$ (978)	30
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares	20,758,166					20,758,166
Net (loss) income	$ (2,563)			(2,567)			4
Cumulative translation adjustment	414				414
Gains (losses) on derivatives qualifying as hedges, net of tax	0
Pension liability and postretirement adjustment; net of tax	(112)				(112)
Cash dividends declared	(827)			(827)
Stock options/SSARs (in shares)						89,850
Stock options/SSARs	0		(4)			$ 4
Vested restricted stock units and awards	(11)		(22)			$ 11
Vested restricted stock units and awards (in shares)						230,222
Stock-based compensation	65		65
Redeemable NCI	(6)		(6)
Dividends on non-controlling interest and other	(3)						(3)
Ending balance (in shares) at Dec. 31, 2023		(275,726,629)
Ending balance at Dec. 31, 2023	$ 14,642	$ 35	$ 19,874	$ (2,439)	$ (1,896)	$ (963)	$ 31
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares	20,438,094					20,438,094